title: The effects of oral hydralazine on blood pressure, cardiac output and peripheral resistance with respect to dose, age and acetylator status.
abstract: Cardiovascular responses are reported in 21 patients with carcinoma of the bronchus taking part in a study of tumour perfusion. There were eight slow and 12 fast acetylators; acetylator status was not determined in one patient with a history of sulphonamide allergy. Hydralazine dose ranged from 25 to 150 mg orally (equivalent to 0.37 to 2.86 mg/kg). Mean arterial blood pressure fell from 98 mmHg before hydralazine to 90 mmHg 60 min after hydralazine (p = 0.002) and mean cardiac output rose from 5.53 l/min to 7.75 l/min (p = 0.00005). Calculated total peripheral resistance fell by 30% (p = 0.0002). Falls in peripheral resistance per milligram hydralazine administered were greater in patients over 70 years of age. Acetylator status was a poor predictor of response. Side-effects were reported by eight patients and were related to the magnitude of fall in peripheral resistance (p = 0.0005) but not to falls in blood pressure (p = 0.12).
authors: Department of Radiotherapy, Royal Marsden Hospital, Sutton, Surrey, U.K.
authors: N P
authors: NP
authors: Rowell
authors: K
authors: K
authors: Clark
mesh_terms: D000107:Acetylation; D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000503:physiopathology*; D002302:Cardiac Output / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000494:pharmacology*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D014655:Vascular Resistance / Q000187:drug effects*
chemical_list: D006830:Hydralazine